October 6, 2023
Immune Biosolutions is pleased to share the most recent findings from our second Phase 1/2 clinical trial (NCT05303376). This study focused on evaluating the safety and efficacy of repeated doses of IBIO123 in treating severe COVID-19 cases among recently hospitalized patients.
Article available in preprint: https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4593223
Immune Biosolutions Enters into a Research Collaboration and License Agreement with Johnson & Johnson Innovation to Identify and Develop Therapeutic…
We are thrilled to welcome a new director to the board of directors of Immune Biosolutions Inc: Mr. Nicholas Franco….
Immune Biosolutions has been selected to present at the 7th International Cancer Cluster Showcase 2018 in Boston during the BIO Convention…
Sherbrooke, Qc, CA, January 15th, 2020 – Immune Biosolutions, an early-stage biopharmaceutical company focusing on the discovery, engineering and development…
After winning a pitch competition earlier this year, Immune Biosolutions’ founders are participating this week in the Futurpreneur’s Growth Accelerator…
Immune Biosolutions is pleased to announce the start of Phase I clinical trial for its immunotherapy (IBIO123) treatment, whose antibodies have the potential to neutralize and eliminate COVID-19 and its variants. The treatment has the ability of being administered by inhalation and acts in a highly targeted manner through the lungs to fight the infection at its source.
